Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

Impact of pretransplant leukemic blast% in bone marrow and peripheral blood on transplantation outcomes of patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation in non-CR

Bone Marrow Transplantation volume 53, pages 478–482 (2018)Cite this article

Subjects

The long-term survival rate of patients who underwent allogeneic SCT (allo-SCT) with a non-CR status was as poor as 10–30% [1–3]; however, a more appropriate indicator of the leukemic burden is needed to assess the prognosis of patients who underwent allo-SCT in non-CR.

Here, we focused on patients with acute myeloid leukemia (AML) who underwent their first allo-SCT with a non-CR status, i.e., primary induction failure (PIF), first relapse (relapse 1), and second relapse (relapse 2), and investigated how the percentage of BM and PB blasts before allo-SCT influenced the transplantation outcomes. To this end, we retrospectively analyzed the data of patients with AML who underwent allo-SCT and were registered in the Transplant Registry Unified Management Program (TRUMP) system, the transplant registry of the Japan Society of Hematopoietic Stem Cell transplantation [4, 5].

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1

References

  1. Duval M, Klein JP, He W, Cahn JY, Cairo M, Camitta BM, et al. Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure. J Clin Oncol. 2010;28:3730–8.

    Article  Google Scholar 

  2. Michallet M, Thomas X, Vernant JP, Kuentz M, Socié G, Espérou-Bourdeau H, et al. Long-term outcome after allogeneic hematopoietic stem cell transplantation for advanced stage acute myeloblastic leukemia: a retrospective study of 379 patients reported to the Société Française de Greffe de Moelle (SFGM). Bone Marrow Transplant. 2000;26:1157–63.

    Article  CAS  Google Scholar 

  3. Oyekunle AA, Kröger N, Zabelina T, Ayuk F, Schieder H, Renges H, et al. Allogeneic stem-cell transplantation in patients with refractory acute leukemia: a long-term follow-up. Bone Marrow Transplant. 2006;37:45–50.

    Article  CAS  Google Scholar 

  4. Atsuta Y. Introduction of Transplant Registry Unified Management Program 2 (TRUMP2): scripts for TRUMP data analyses, part I (variables other than HLA-related data). Int J Hematol. 2016;103:3–10.

    Article  Google Scholar 

  5. Kanda J. Scripts for TRUMP data analyses. Part II (HLA-related data): statistical analyses specific for hematopoietic stem cell transplantation. Int J Hematol. 2016;103:11–9.

    Article  CAS  Google Scholar 

  6. Miyawaki S, Sakamaki H, Ohtake S, et al. A randomized, postremission comparison of four courses of standard-dose consolidation therapy without maintenance therapy versus three courses of standard-dose consolidation with maintenance therapy in adults with acute myeloid leukemia: the Japan Adult Leukemia Study Group AML 97 Study. Cancer. 2005;104:2726–34.

    Article  CAS  Google Scholar 

  7. Miyawaki S, Ohtake S, Fujisawa S, et al. A randomized comparison of 4 courses of standard-dose multiagent chemotherapy versus 3 courses of high-dose cytarabine alone in postremission therapy for acute myeloid leukemia in adults: the JALSG AML201 Study. Blood. 2011;117:2366–72.

    Article  CAS  Google Scholar 

  8. Stern M, Brand R, de Witte T, Sureda A, Rocha V, Passweg J, et al. Female-versus-male alloreactivity as a model for minor histocompatibility antigens in hematopoietic stem cell transplantation. Am J Transplant. 2008;8:2149–57.

    Article  CAS  Google Scholar 

  9. Gratwohl A. The EBMT risk score. Bone Marrow Transplant. 2012;47:749–56.

    Article  CAS  Google Scholar 

  10. Grimwade D, Hills RK, Moorman AV, Walker H, Chatters S, Goldstone AH, et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood. 2010;116:354–65.

    Article  CAS  Google Scholar 

  11. Giralt S, Ballen K, Rizzo D, Bacigalupo A, Horowitz M, Pasquini M, et al. Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research. Biol Blood Marrow Transplant. 2009;15:367–9.

    Article  Google Scholar 

Download references

Acknowledgements

This research was partially supported by the Practical Research Project for Allergic Diseases and Immunology (Research on Technology of Medical Transplantation) from the Japan Agency for Medical Research and Development, AMED.

Author information

Author notes

  1. Hiroyasu Ogawa and Kazuhiro Ikegame contributed equally to this work.

Authors and Affiliations

  1. Division of Hematology, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan

    Hiroyasu Ogawa & Kazuhiro Ikegame

  2. Department of Biostatistics, Hyogo College of Medicine, Nishinomiya, Japan

    Takashi Daimon

  3. Department of Hematology, Federation of National Public Service Personnel Mutual Aid Associations, Toranomon Hospital, Tokyo, Japan

    Naoyuki Uchida

  4. Department of Hematopoetic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan

    Takayuki Fukuda

  5. Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan

    Kazuhiko Kakihana

  6. Department of Hematology, Hamanomachi Hospital, Fukuoka, Japan

    Tetsuya Eto

  7. Department of Hematology, Japanese Red Cross Nagoya First Hospital, Nagoya, Japan

    Yukiyasu Ozawa

  8. Department of Hematology, Kanagawa Cancer Center, Yokohama, Japan

    Heiwa Kanamori

  9. Department of Hematology, National Hospital Organization Kumamoto Medical Center, Kumamoto, Japan

    Michihiro Hidaka

  10. Department of Hematology, Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital, Hiroshima, Japan

    Yasuharu Iwato

  11. Department of Hematology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Higashihiroshima, Japan

    Tatsuo Ichinohe

  12. Blood Service Headquarters, Japanese Red Cross Society, Tokyo, Japan

    Minoko Takanashi

  13. Japanese Data Center for Hematopoietic Cell Transplantation, Department of Healthcare Administration, Nagoya University Graduate School of Medicine, Nagoya, Japan

    Yoshiko Atsuta

  14. Division of Hematology, Saitama Medical Center, Jichi Medical University, Shimotsuke, Japan

    Yoshinobu Kanda

Authors
  1. Hiroyasu Ogawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kazuhiro Ikegame
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Takashi Daimon
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Naoyuki Uchida
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Takayuki Fukuda
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Kazuhiko Kakihana
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Tetsuya Eto
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Yukiyasu Ozawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Heiwa Kanamori
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Michihiro Hidaka
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Yasuharu Iwato
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Tatsuo Ichinohe
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Minoko Takanashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Yoshiko Atsuta
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Yoshinobu Kanda
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hiroyasu Ogawa.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interests.

Electronic supplementary material

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ogawa, H., Ikegame, K., Daimon, T. et al. Impact of pretransplant leukemic blast% in bone marrow and peripheral blood on transplantation outcomes of patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation in non-CR. Bone Marrow Transplant 53, 478–482 (2018). https://doi.org/10.1038/s41409-017-0028-x

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41409-017-0028-x

This article is cited by

Search

Advanced search

Quick links